Le microenvironnement des cellules tumorales présente plusieurs particularités comme l'hypoxie, l'acidification du milieu extracellulaire et l'hypersécrétion d'enzymes hydrolytiques. Ces hydrolases, comme la cathepsine D et l'héparanase, interviennent dans les étapes de la progression tumorale et notamment l'angiogenèse. Cette thèse s'intègre dans un projet dont la finalité est de concevoir un nano-objet moléculaire enzymo-sensible qui réagirait d'une manière spécifique aux enzymes hypersécrétées dans le microenvironnement tumoral pour assurer de façon simultanée, une fonction de détection et de ciblage des tumeurs. La première partie de nos travaux a été consacrée à la conception et à la validation d'un lien peptidique intégrable dans l'objet moléculaire, sensible aux formes de la cathepsine D actives du microenvironnement tumoral de cancers mammaires. Cet objectif a été réalisé suite à l'étude cinétique de l'hydrolyse de 5 peptides par la cathepsine D mature et la pro-cathepsine D dans les conditions de pH du microenvironnement tumoral. Nous avons également étudié l'effet de l'hypoxie et de l'acidification du milieu extracellulaire sur la sécrétion des formes actives de la cathepsine D par la lignée tumorale de cancer mammaire MCF-7. Dans une deuxième partie, nous avons travaillé sur l'élaboration d'héparines de bas poids moléculaire pouvant assurer la fonction thérapeutique de l'objet moléculaire grâce à leur activité anti-angiogénique. Nous avons mis au point une méthode innovante pour la dépolymérisation de l'héparine qui consiste en une hydrolyse radicalaire par le péroxyde d'hydrogène assistée par les ultrasons. Cette technique permet la production d'oligosaccharides d'héparines caractérisées par des poids moléculaires et des degrés de sulfatation contrôlés. En fonction des conditions de dépolymérisation par cette technique, les héparines de bas poids moléculaires produites peuvent être utilisées comme anticoagulant ou anti-angiogénique. / Tumor microenvironment is characterized by several particularities such as hypoxia, extracellular media acidification and the hyper-secretion of hydrolytic enzymes. These hydrolases, such as cathepsin D and heparanase, are involved in many steps of tumor progression like angiogenesis. This thesis is a part of a project that aims to develop a "smart" molecular nano-object that specifically reacts to hyper-secreted enzymes in the tumor microenvironment for the simultaneous detection and targeting of tumor. The first part of our work concerned the design and the validation of a peptide that is sensitive to active forms of cathepsin D which is a protease, unregulated in many tumors microenvironment such as breast cancers. This objective has been achieved following the kinetic study of the hydrolysis of 5 peptides by mature cathepsin D and procathepsin D in the pH conditions of the tumor microenvironment. On the other hand, we studied the effect of hypoxia and the acidification of the extracellular medium on the secretion of active forms of cathepsin D by the breast cancer cell line MCF-7. In a second part, we worked on the development of low molecular weight heparins that may provide therapeutic function of the molecular object through their anti-angiogenic activity. We have developed an innovative method for the depolymerization of heparin that consists on a radical hydrogen peroxide hydrolysis assisted by ultrasound. This technique allows the production of heparins oligosaccharides characterized by controlled molecular weight and degree of sulfatation. Depending on the depolymerization conditions by this technique, the produced low molecular weight heparins can be used as an anticoagulant or anti-angiogenic.

Le collagène de type I osseux subit une série de modifications post-traductionnelles au cours du processus de maturation. Un certain nombre de ces modifications sont quantifiables par dosage : c’est le cas des molécules de pontage enzymatiques pyridinoline (PYD) et désoxypyridinoline (DPD), de la pentosidine (PEN) qui est un produit de glycation, et de la forme native (α) et isomérisée (β) des C-télopeptides (α et β CTX) du collagène de type I. A l’aide d’un modèle de maturation in vitro d’os bovin foetal, nous avons montré que le taux de solubilisation du collagène osseux par la cathepsine K augmente avec la durée d’incubation des os à 37°C. Nous avons également montré que cette augmentation est corrélée au taux des modifications post-traductionnelles du collagène mesurées. Lors d’une étude précédente utilisant ce même modèle de maturation d’os foetal, nous avions déterminé que les modifications post-traductionnelles du collagène osseux influençaient les propriétés mécaniques de l’os. Dans le cadre de ce travail de thèse et pour compléter cette étude, nous avons mis au point un modèle pour étudier isolément l’influence des molécules de pontage PYD et DPD sur les propriétés mécaniques de l’os. Ce modèle utilise de l’os cortical bovin traité aux U.V. puis soumis à des tests de flexion trois points. Dans la même optique, nous avons contribué à la mise au point d’un dosage en chromatographie en phase liquide à haute performance qui permet de quantifier à la fois les formes matures et immatures des molécules de pontage pyridinoliques (PYD, DPD, HLNL et DHLNL) sur le même chromatogramme / Type I bone collagen undergoes a series of posttranslational modifications during maturation process. Some of them are quantifiable by assays: the enzymatic cross-links pyridinoline (PYD) and deoxypyridinoline (DPD), the advanced glycation end product pentosidine (PEN), and the native (α) and isomerized (β) forms of the type I collagen C-telopeptides (α and β CTX). With an in vitro model of bovine fetal bone maturation, we showed that bone collagen solubilization by cathepsin K increases with the duration of bone incubation at 37°C. We also showed a correlation between this increase of solubilization and the level of measured collagen posttranslational modifications. In a previous study, using the same fetal bovine bone maturation, our results had suggested a link between bone collagen posttranslational modifications and bone mechanical properties. In the aim to complete this study, we developed a model to focus on PYD and DPD influence in bone mechanical properties. This model uses bovine cortical bone subjected to ultraviolet light before three points binding tests. In the same purpose, we contributed to develop a High-Performance Liquid Chromatography essay, quantifying mature and immature forms of pyridinium crosslinks (PYD, DPD, HLNL and DHLNL) in an unique chromatogram

Les ostéoclastes, les seules cellules capables de résorber l’os, sont soupçonnés d’être associés au développement et à la progression des radiotransparences sous-chondrales (SR). Ils n’ont par contre jamais été étudiés in situ. Les objectifs de cette étude cadavérique ex vivo étaient de mesurer et de comparer la densité ostéoclastique et le pourcentage de chondroclastes se trouvant à différentes profondeurs de l’os sous-chondral à partir de la surface articulaire dans le condyle fémoral médial (CFM) de chevaux Pur-sang juvéniles sains et atteints de SR hâtives spontanées. Les spécimens provenaient d’une banque de tissus et faisaient partie d’une étude précédente sur les caractéristiques structurelles des SR. La tomodensitométrie identifiait les CFM atteints de SR (n=6) et guidait les coupes ostéochondrales. Les contrôles de l’étude étaient composés d’un site histologiquement normal et caudal à la lésion (n=6) et du site controlatéral à la lésion dans le CFM sain (n=5). Après la décalcification et la fixation dans la paraffine, les spécimens étaient colorés à l’immunohistochimie afin de mettre en évidence les ostéoclastes présents dans l’os en périphérie des SR. Les spécimens étaient ensuite séparés en régions d’intérêt (ROI) à différentes profondeurs de l’os sous-chondral: ROI1 (0-1mm), ROI2 (1-3mm) et ROI3 (3-6mm). Les ostéoclastes ont été comptés dans chaque ROI pour calculer leur densité ostéoclastique respective. Les lames ont été contre-colorées avec la Safranine afin d’identifier le cartilage et mesurer le pourcentage de chondroclastes. La densité ostéoclastique était statistiquement plus élevée dans la ROI1 comparativement à la ROI3 dans tous les groupes. Cependant, aucune différence significative n’a été détectée en comparant les ROI entre les groupes, même si la densité ostéoclastique était supérieure dans la ROI1 des SR. Malgré une proportion de chondroclastes dans la ROI1 des SR inférieure à celle des contrôles, aucune différence significative n’a été détectée. La limite principale de cette étude se révéla être la taille de l’échantillon. Nos résultats démontrent cependant que la pathophysiologie des SR n’est pas uniquement expliquée par l’augmentation du nombre d’ostéoclastes dans l’os sous-chondral en périphérie des lésions. / There is a knowledge gap concerning how and when equine medial femoral condyle (MFC) subchondral radiolucencies (SR) arise and evolve. Osteoclasts, the only cells capable of bone resorption, are believed to have a role, but have not been studied in situ. The objectives of this ex vivo cadaveric study were to measure and compare the osteoclast density and the percentage of chondroclasts in juvenile (<1 year) Thoroughbred MFCs at varying depths from the weightbearing articular surface in both healthy and early spontaneous MFC SR specimens. The MFCs were available in a tissue bank and were part of a prior study of the structural characteristics of SRs. Computed tomography permitted identification of MFC SR (n=6) and guided osteochondral slab sections. Controls included a histologically normal site caudal to the lesions (n=6) and the healthy contralateral MFC lesion site (n=5). Following decalcification, paraffin embedding sections were cut and stained immunohistochemically with Cathepsin K to permit osteoclast identification and counting. The sections were divided into regions of interest (ROI) at different depths in the subchondral bone from the osteochondral junction: ROI1 (0-1mm), ROI2 (1-3mm) and ROI3 (3-6mm). Osteoclasts were counted in each ROI in order to calculate an osteoclast density. A Safranin-O counterstain was performed to identify the cartilage and measure the chondroclasts percentage. Osteoclast density was significantly higher in ROI1 when compared with ROI3 in all groups. When ROIs were compared between the three groups, no statistically significant differences were detected, even if a visible pattern difference and higher osteoclast density values were recorded in ROI1 in SRs. However, although the proportion of chondroclasts in ROI1 was lower in the SR sections when compared with controls, no significant difference was detected. The main limitation was the limited sample size. Osteoclasts are important actors in MFC subchondral bone development, digesting both growth cartilage (chondroclasts) and bone, but the pathophysiology of early MFC SRs cannot be explained solely by an increased osteoclast presence in the peripheral subchondral bone.

Fascioloides magna (the giant liver fluke) originated from North America, is known in the Czech Republic since 1930s. This pathogenic fluke invades mostly cervids, but livestock too. Excretory-secretory products (ES products) contain number of esential biomolecules which are produced by excretory and secretory system of the fluke. These molecules play key role in many biological process during the life cycle not only of fascioloid flukes (e.g. migration in the host tissues, immune evasion and digestion). Due to their antigenic properties they could be also used in immunodiagnostics. Excretory-secretory proteins from adult Fascioloides magna and comparative related species Fasciola hepatica were purified and separated by the basic biochemical methods (1D, 2D electrophoresis, ion-exchange chromatography) and their activity was confirmed by specific (fluorogenic peptide) and nonspecific (gelatine) substrates. By using the mass spectrometry methods (MALDI TOF/TOF), the most abundant peptidolytically active proteins from ES products of F. magna were identified as cathepsin L (FmCL). Recombinant analog of FmCL was expressed in Pichia pastoris expression system. The peptidolytic activity was again confirmed using the synthetic fluorogenic substrates; the specifity of recombinant FmCL active site was...

No description available.

Le CD40 est une glycoprotéine transmembranaire de type I, appartenant à la famille des TNFRs, exprimée à la surface des cellules immunitaires, hématopoïétiques, vasculaires, épithéliales, et d’autres types de cellules, y compris les cellules tumorales. Le CD40 ne possédant pas de domaine kinase, pour induire un signal il interagit directement ou indirectement avec des protéines adaptatrices telles que les TRAFs et les JAKs. L’interaction du CD40 avec son principal ligand, le CD154, joue un rôle primordial dans la régulation de la réponse immunitaire et le maintien de l’homéostasie. L’activation du CD40 à la surface des cellules B augmente leur capacité de présentation d’antigène, en plus d’induire la prolifération, la commutation isotypique et l’apoptose. Les patients souffrant de mutations au niveau du gène codant pour le CD40 ou de son ligand sont immunosupprimés et sensibles à des infections opportunistes. Des études ont montré que le CD40 comme d’autres membres de la famille des TNFRs est capable de former des homodimères. Plus récemment, on a montré que la formation du CD40 homodimère est le résultat de son engagement sur les cellules B. En plus, cette homodimérisation du CD40 est importante pour la phosphorylation de l’Akt. L’interaction CD40/CD154 peut avoir un rôle direct dans l’immunothérapie par l’induction de l’apoptose de certaines cellules cancéreuses ou un rôle indirect en activant les cellules présentatrices d’antigènes (CPA) afin d'augmenter l’efficacité de l’activation des cellules T cytotoxiques. Nos résultats montrent que l’induction de la mort cellulaire par le CD40 requiert la perméabilisation du lysosome, la libération de la cathepsine B, la présence de ROS et une interaction avec le TRAF6, cette mort cellulaire programmée est plus importante en présence de la forme monomérique du CD40, muté au niveau de la cystéine 238. Par ailleurs, l’homodimérisation du CD40 requerrait sa translocation vers les radeaux lipidiques et nécessiterait la présence des ROS. Cette homodimérisation du CD40 semble être importante pour l’activation des cellules B par le biais de l’induction de l’expression du CD23, CD69 et CD80. De plus, nos résultats montrent pour la première fois une implication du CD40 homodimère dans l’induction du CD23 par le biais du TLR4. Nos résultats soulignent l’importance du CD40 homodimère dans certaines voies de signalisation. Ainsi, ils mettent en évidence le rôle de la Cys-238 dans la coopération entre des récepteurs de la réponse immunitaire innée et adaptative. Toutes ces données permettraient une meilleure compréhension de certaines voies de signalisation impliquées dans plusieurs maladies auto-immunes et faisant objet de plusieurs essais thérapeutiques. / CD40 is a type I transmembrane glycoprotein belonging to the TNFRs family, which is expressed on the surface of immune, hematopoietic cells, vascular, epithelial, and other cell types, including a wide range of tumour cells. CD40 does not have a kinase domain. Thus, to induce a signal, CD40 interacts directly or indirectly with adapter proteins such as TRAFs and Jaks. The interaction of CD40 with its main ligand, CD154, plays an important role in regulating the immune response and homeostasis. The activation of CD40 on the surface of B cells increases its ability to promote antigen presentation, in addition to inducing proliferation, isotype switching, and apoptosis. Patients affected by mutations in the gene encoding the CD40 or its ligand are immunosuppressed and susceptible to opportunistic infections. Studies have shown that CD40, as other members of the family of TNFRs is capable of forming homodimers. More recently, it was shown that the formation of the CD40 homodimer is the result of the engagement of CD40 on B cells by CD154. In addition, the homodimerization of CD40 is important for the phosphorylation of Akt. The CD40/CD154 interaction can have a direct role in immunotherapy by inducing apoptosis of some cancer cells or an indirect role in activating antigen-presenting cells (APCs), thereby increasing the effectiveness of activation of cytotoxic T cells. Our results show that the induction of cell death by CD40 requires permeabilization of the lysosome, the release of cathepsin B, the presence of ROS and interaction with TRAF6, this programmed cell death is greater in the presence of the monomeric form of CD40, due to a mutation at the level of the cysteine 238. Moreover, the homodimerization of CD40 requires its translocation to lipid rafts and the presence of ROS. This homodimerization is necessary for the CD40 B-cell activation via the induction of expression of CD23, CD69 and CD80. In addition, our results show for the first time the involvement of the CD40 homodimer in the induction of CD23 expression via TLR4. Our results emphasize the importance of CD40 homodimer in signaling pathways and highlight the role of Cys-238 in the cooperation between receptors of the innate and adaptive immune response. All together our results will allow a better understanding of CD40 signaling pathways involved in several autoimmune diseases, which give a rise to a better therapeutic trial design.

Le CD40 est une glycoprotéine transmembranaire de type I, appartenant à la famille des TNFRs, exprimée à la surface des cellules immunitaires, hématopoïétiques, vasculaires, épithéliales, et d’autres types de cellules, y compris les cellules tumorales. Le CD40 ne possédant pas de domaine kinase, pour induire un signal il interagit directement ou indirectement avec des protéines adaptatrices telles que les TRAFs et les JAKs. L’interaction du CD40 avec son principal ligand, le CD154, joue un rôle primordial dans la régulation de la réponse immunitaire et le maintien de l’homéostasie. L’activation du CD40 à la surface des cellules B augmente leur capacité de présentation d’antigène, en plus d’induire la prolifération, la commutation isotypique et l’apoptose. Les patients souffrant de mutations au niveau du gène codant pour le CD40 ou de son ligand sont immunosupprimés et sensibles à des infections opportunistes. Des études ont montré que le CD40 comme d’autres membres de la famille des TNFRs est capable de former des homodimères. Plus récemment, on a montré que la formation du CD40 homodimère est le résultat de son engagement sur les cellules B. En plus, cette homodimérisation du CD40 est importante pour la phosphorylation de l’Akt. L’interaction CD40/CD154 peut avoir un rôle direct dans l’immunothérapie par l’induction de l’apoptose de certaines cellules cancéreuses ou un rôle indirect en activant les cellules présentatrices d’antigènes (CPA) afin d'augmenter l’efficacité de l’activation des cellules T cytotoxiques. Nos résultats montrent que l’induction de la mort cellulaire par le CD40 requiert la perméabilisation du lysosome, la libération de la cathepsine B, la présence de ROS et une interaction avec le TRAF6, cette mort cellulaire programmée est plus importante en présence de la forme monomérique du CD40, muté au niveau de la cystéine 238. Par ailleurs, l’homodimérisation du CD40 requerrait sa translocation vers les radeaux lipidiques et nécessiterait la présence des ROS. Cette homodimérisation du CD40 semble être importante pour l’activation des cellules B par le biais de l’induction de l’expression du CD23, CD69 et CD80. De plus, nos résultats montrent pour la première fois une implication du CD40 homodimère dans l’induction du CD23 par le biais du TLR4. Nos résultats soulignent l’importance du CD40 homodimère dans certaines voies de signalisation. Ainsi, ils mettent en évidence le rôle de la Cys-238 dans la coopération entre des récepteurs de la réponse immunitaire innée et adaptative. Toutes ces données permettraient une meilleure compréhension de certaines voies de signalisation impliquées dans plusieurs maladies auto-immunes et faisant objet de plusieurs essais thérapeutiques. / CD40 is a type I transmembrane glycoprotein belonging to the TNFRs family, which is expressed on the surface of immune, hematopoietic cells, vascular, epithelial, and other cell types, including a wide range of tumour cells. CD40 does not have a kinase domain. Thus, to induce a signal, CD40 interacts directly or indirectly with adapter proteins such as TRAFs and Jaks. The interaction of CD40 with its main ligand, CD154, plays an important role in regulating the immune response and homeostasis. The activation of CD40 on the surface of B cells increases its ability to promote antigen presentation, in addition to inducing proliferation, isotype switching, and apoptosis. Patients affected by mutations in the gene encoding the CD40 or its ligand are immunosuppressed and susceptible to opportunistic infections. Studies have shown that CD40, as other members of the family of TNFRs is capable of forming homodimers. More recently, it was shown that the formation of the CD40 homodimer is the result of the engagement of CD40 on B cells by CD154. In addition, the homodimerization of CD40 is important for the phosphorylation of Akt. The CD40/CD154 interaction can have a direct role in immunotherapy by inducing apoptosis of some cancer cells or an indirect role in activating antigen-presenting cells (APCs), thereby increasing the effectiveness of activation of cytotoxic T cells. Our results show that the induction of cell death by CD40 requires permeabilization of the lysosome, the release of cathepsin B, the presence of ROS and interaction with TRAF6, this programmed cell death is greater in the presence of the monomeric form of CD40, due to a mutation at the level of the cysteine 238. Moreover, the homodimerization of CD40 requires its translocation to lipid rafts and the presence of ROS. This homodimerization is necessary for the CD40 B-cell activation via the induction of expression of CD23, CD69 and CD80. In addition, our results show for the first time the involvement of the CD40 homodimer in the induction of CD23 expression via TLR4. Our results emphasize the importance of CD40 homodimer in signaling pathways and highlight the role of Cys-238 in the cooperation between receptors of the innate and adaptive immune response. All together our results will allow a better understanding of CD40 signaling pathways involved in several autoimmune diseases, which give a rise to a better therapeutic trial design.

A L-Asparaginase II de Escherichia coli (EcA II) é uma enzima amplamente utilizada no tratamento da Leucemia Linfoblástica Aguda (LLA), atuando na depleção do aminoácido L-asparagina, o qual é fundamental para a multiplicação das células cancerosas. Contudo, o tratamento com a EcA II está associado a altos índices de hipersensibilidade, devido à formação de anticorpos anti-L-asparaginase e à clivagem da enzima pelas proteases sanguíneas asparagina endopeptidase (AEP) e catepsina B (CTSB). Também ocorre neurotoxicidade associada ao efeito L-glutaminase da enzima. O principal objetivo do presente trabalho é a obtenção de mutantes da EcA II (gene ansB) com equivalente eficiência catalítica, maior resistência à clivagem proteolítica e menor atividade glutaminase. Para este propósito, através da reação em cadeia da polimerase propensa a erro (epPCR) do gene ansB, foi construída uma biblioteca de 1128 clones expressos no vetor pET15b em BL21(DE3). Nenhum mutante com atividade asparaginásica equivalente à EcA II selvagem apresentou atividade glutaminásica inferior à esta. Dentre os clones triados obtivemos um mutante (T161I) resistente à clivagem proteolítica pela CTSB e dois mutantes (Q190L e P40S/S206C) resistentes à clivagem proteolítica por ambas AEP e CTSB. Estes três mutantes apresentaram atividade asparaginásica e glutaminásica equivalentes a EcA II selvagem. Nossos resultados mostram promissoras possibilidades de EcA II mutantes com maior estabilidade frente às proteases sanguíneas humanas e possivelmente menos imunogênicas. / Escherichia coli L-asparaginase (EcA II) is an enzyme widely used in the treatment of acute lymphoblastic leukemia (ALL), acting in the depletion of the amino acid L-asparagine, which is essential for cancer cells proliferation. However, treatment with L-asparaginase is associated with a high rate of hypersensitivity, due to formation of anti-L-asparaginase antibody and the enzyme cleavage by the serum proteases asparagine endopeptidase (AEP) and cathepsin B (CTSB). Furthermore, the neurotoxicity is associated with the effect of the enzyme L-glutaminase activity. The main aim of the current work is to obtain variants of EcA II (gene ansB) with an equivalent catalytic efficiency, greater resistance to proteolytic cleavage and a reduced glutaminase activity. For such purpose, through error-prone polymerase chain reaction (epPCR) of gene ansB, a library of 1128 clones was constructed in pET15b vector and expressed in BL21(DE3). None mutant with an asparaginase activity equivalent to EcA II wild type showed a reduced glutaminase activity. Among the screened clones, one mutant (T161I) was resistant to CTSB proteolytic cleavage and two mutants (Q190L e P40S/S206C) were resistant to both CTSB and AEP proteolytic cleavages. These three mutants were EcA II wild type equivalents in asparaginase and glutaminase activities. Our data show promising new possibilities of mutant EcA II presenting higher stability against human serum proteolytic cleavage and maybe lower immunogenicity.

A primeira parte desta tese aborda estudos sobre a reatividade de compostos de telúrio eletrofílicos, principalmente tetracloreto de telúrio e tricloretos aromáticos de telúrio. Novos aspectos da reatividade de TeCl4 frente a alcinos e algumas acetofenonas foram observados e, a partir da elucidação estrutural dos compostos obtidos, por cristalografia, uma racionalização mecanística foi proposta para cada caso. As proposições apresentadas encontraram respaldo com a detecção de intermediários transientes por estudos de espectrometria de massas com ionização por electron-spray (ESI-MS/MS). Além de novos aspectos da química do Telúrio, os compostos preparados encontraram aplicação como potentes e seletivos inibidores de cisteíno proteases. Com esta aplicação estabelecida, foram sintetizadas ambos os enantiômeros de uma telurana e a atividade inibitória destas frente a Catepsina B mostrou dependência da estereoquímica devido a dependência estereoquímica da interação entre a enzima e o inibidor. A segunda parte deste trabalho trata do desenvolvimento da reação de abertura de anel de aziridinas por reagentes organometálicos de cobre derivados de teluretos vinílicos e arílicos que resultaram em derivados de aminas homoalílicas ou homobenzílicas. Em seguida, a reatividade de aziridinas alílicas foi estudada frente a uma série de reagentes organometálicos de lítio, magnésio, cobre e zinco que mostraram influenciar a regio- e estereosseletividades das reações de abertura. / The first part of this thesis deals with the study of the reactivity of electrophilic tellurium compounds, mainly tellurium tetrachloride and aromatic tellurium trichlorides. New aspects of the reactivity of TeCl4 towards alkynes and some acetophenones were disclosed. A mechanistic rationale for each of the processes studied was possible by the determination of the stereochemistry for each product by monocrystal X-ray diffraction analysis. The proposition of the formation of cationic intermediates in the addition reaction of TeCl4 to alkynes was corroborated by the detection and characterization of transient intermediates by ESI-MS/MS experiments. Besides the new aspects of the Tellurium chemistry found, the prepared compounds showed a high and selective activity as inhibitors of cysteine proteases. A pair of enantiomers of a tellurane showed different activities against Human Catepsin B due to a stereochemical dependence in the enzyme/inhibitor interaction. The second part of the present work deals with the development of the ring opening reaction of aziridines by organometallic reagents of copper prepared from vinylic and arylic tellurides. These reactions led to homoallylic and homobenzylic amine derivatives. Finally, the reactivity of 2-alkenyl aziridines was studied towards a series of organometallic reagents of lithium, magnesium, copper and zinc which biased the regio- and stereoselectivities of the ring opening reactions.

A L-Asparaginase II de Escherichia coli (EcA II) é uma enzima amplamente utilizada no tratamento da Leucemia Linfoblástica Aguda (LLA), atuando na depleção do aminoácido L-asparagina, o qual é fundamental para a multiplicação das células cancerosas. Contudo, o tratamento com a EcA II está associado a altos índices de hipersensibilidade, devido à formação de anticorpos anti-L-asparaginase e à clivagem da enzima pelas proteases sanguíneas asparagina endopeptidase (AEP) e catepsina B (CTSB). Também ocorre neurotoxicidade associada ao efeito L-glutaminase da enzima. O principal objetivo do presente trabalho é a obtenção de mutantes da EcA II (gene ansB) com equivalente eficiência catalítica, maior resistência à clivagem proteolítica e menor atividade glutaminase. Para este propósito, através da reação em cadeia da polimerase propensa a erro (epPCR) do gene ansB, foi construída uma biblioteca de 1128 clones expressos no vetor pET15b em BL21(DE3). Nenhum mutante com atividade asparaginásica equivalente à EcA II selvagem apresentou atividade glutaminásica inferior à esta. Dentre os clones triados obtivemos um mutante (T161I) resistente à clivagem proteolítica pela CTSB e dois mutantes (Q190L e P40S/S206C) resistentes à clivagem proteolítica por ambas AEP e CTSB. Estes três mutantes apresentaram atividade asparaginásica e glutaminásica equivalentes a EcA II selvagem. Nossos resultados mostram promissoras possibilidades de EcA II mutantes com maior estabilidade frente às proteases sanguíneas humanas e possivelmente menos imunogênicas. / Escherichia coli L-asparaginase (EcA II) is an enzyme widely used in the treatment of acute lymphoblastic leukemia (ALL), acting in the depletion of the amino acid L-asparagine, which is essential for cancer cells proliferation. However, treatment with L-asparaginase is associated with a high rate of hypersensitivity, due to formation of anti-L-asparaginase antibody and the enzyme cleavage by the serum proteases asparagine endopeptidase (AEP) and cathepsin B (CTSB). Furthermore, the neurotoxicity is associated with the effect of the enzyme L-glutaminase activity. The main aim of the current work is to obtain variants of EcA II (gene ansB) with an equivalent catalytic efficiency, greater resistance to proteolytic cleavage and a reduced glutaminase activity. For such purpose, through error-prone polymerase chain reaction (epPCR) of gene ansB, a library of 1128 clones was constructed in pET15b vector and expressed in BL21(DE3). None mutant with an asparaginase activity equivalent to EcA II wild type showed a reduced glutaminase activity. Among the screened clones, one mutant (T161I) was resistant to CTSB proteolytic cleavage and two mutants (Q190L e P40S/S206C) were resistant to both CTSB and AEP proteolytic cleavages. These three mutants were EcA II wild type equivalents in asparaginase and glutaminase activities. Our data show promising new possibilities of mutant EcA II presenting higher stability against human serum proteolytic cleavage and maybe lower immunogenicity.